Executive Summary: Global Antibody-Drug Conjugate (ADC) Market

2.1. Research Objective

2.2. Product Overview

2.3. Market Segmentation

2.4. Qualitative Research
2.4.1. Primary & Secondary Sources

2.5. Quantitative Research
2.5.1. Primary & Secondary Sources

2.6. Breakdown of Primary Research Respondents, By Region

2.7. Assumption for Study

2.8. Market Size Estimation

2.9. Data Triangulation

3.1. Industry Value Chain Analysis
3.1.1. Antibody, Payload & Linker Component Suppliers
3.1.2. ADC Bioconjugation & Contract Manufacturers (CDMOs)
3.1.3. ADC Drug Developers & Biopharma Companies
3.1.4. Regulatory, Distribution & Specialty Pharmacy Channels
3.1.5. Healthcare Providers (Hospitals, Cancer Centers) & Patients

3.2. Industry Outlook
3.2.1. Overview of the Global Targeted Oncology & ADC Therapeutics Industry
3.2.2. Pipeline Expansion, Approvals & Licensing / M&A Activity
3.2.3. Next-Generation Payloads, Linkers & Bispecific ADC Innovation

3.3. PESTLE Analysis

3.4. Porter's Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitutes
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition

3.5. Market Growth and Outlook
3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
3.5.2. Price Trend Analysis, By Product

4.1. Competition Dashboard
4.1.1. Market Concentration Rate
4.1.2. Company Market Share Analysis (Value %), 2025
4.1.3. Competitor Mapping & Benchmarking

5.1. Market Dynamics and Trends
5.1.1. Growth Drivers
5.1.2. Restraints
5.1.3. Opportunity
5.1.4. Key Trends

5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
5.2.1. By Product
5.2.1.1. Key Insights
5.2.1.1.1. Kadcyla
5.2.1.1.2. Enhertu
5.2.1.1.3. Adcetris
5.2.1.1.4. Padcev
5.2.1.1.5. Trodelvy
5.2.1.1.6. Polivy
5.2.1.1.7. Blenrep
5.2.1.1.8. Others
5.2.2. By Target Antigen
5.2.2.1. Key Insights
5.2.2.1.1. HER2
5.2.2.1.2. CD30
5.2.2.1.3. TROP-2
5.2.2.1.4. CD22
5.2.2.1.5. Nectin-4
5.2.2.1.6. BCMA
5.2.2.1.7. Others
5.2.3. By Payload / Technology
5.2.3.1. Key Insights
5.2.3.1.1. Auristatins (MMAE / MMAF)
5.2.3.1.2. Maytansinoids (DM1 / DM4)
5.2.3.1.3. Calicheamicins
5.2.3.1.4. Topoisomerase Inhibitors (DXd)
5.2.3.1.5. Others
5.2.4. By Linker Type
5.2.4.1. Key Insights
5.2.4.1.1. Cleavable
5.2.4.1.2. Non-Cleavable
5.2.5. By Indication
5.2.5.1. Key Insights
5.2.5.1.1. Breast Cancer
5.2.5.1.2. Hematologic / Blood Cancers
5.2.5.1.3. Lung Cancer
5.2.5.1.4. Bladder / Urothelial Cancer
5.2.5.1.5. Ovarian Cancer
5.2.5.1.6. Others
5.2.6. By End User
5.2.6.1. Key Insights
5.2.6.1.1. Hospitals
5.2.6.1.2. Specialty & Cancer Centers
5.2.6.1.3. Others
5.2.7. By Region
5.2.7.1. Key Insights
5.2.7.1.1. North America
5.2.7.1.1.1. The U.S.
5.2.7.1.1.2. Canada
5.2.7.1.1.3. Mexico
5.2.7.1.2. Europe
5.2.7.1.2.1. Western Europe
5.2.7.1.2.1.1. The UK
5.2.7.1.2.1.2. Germany
5.2.7.1.2.1.3. France
5.2.7.1.2.1.4. Italy
5.2.7.1.2.1.5. Spain
5.2.7.1.2.1.6. Rest of Western Europe
5.2.7.1.2.2. Eastern Europe
5.2.7.1.2.2.1. Poland
5.2.7.1.2.2.2. Russia
5.2.7.1.2.2.3. Rest of Eastern Europe
5.2.7.1.3. Asia Pacific
5.2.7.1.3.1. China
5.2.7.1.3.2. India
5.2.7.1.3.3. Japan
5.2.7.1.3.4. Australia & New Zealand
5.2.7.1.3.5. South Korea
5.2.7.1.3.6. ASEAN
5.2.7.1.3.7. Rest of Asia Pacific
5.2.7.1.4. Middle East & Africa (MEA)
5.2.7.1.4.1. Saudi Arabia
5.2.7.1.4.2. South Africa
5.2.7.1.4.3. UAE
5.2.7.1.4.4. Rest of MEA
5.2.7.1.5. South America
5.2.7.1.5.1. Argentina
5.2.7.1.5.2. Brazil
5.2.7.1.5.3. Rest of South America

6.1. Market Dynamics and Trends
6.1.1. Growth Drivers
6.1.2. Restraints
6.1.3. Opportunity
6.1.4. Key Trends

6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
6.2.1. Key Insights
6.2.1.1. By Product
6.2.1.2. By Target Antigen
6.2.1.3. By Payload / Technology
6.2.1.4. By Linker Type
6.2.1.5. By Indication
6.2.1.6. By End User
6.2.1.7. By Country

7.1. Market Dynamics and Trends
7.1.1. Growth Drivers
7.1.2. Restraints
7.1.3. Opportunity
7.1.4. Key Trends

7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
7.2.1. Key Insights
7.2.1.1. By Product
7.2.1.2. By Target Antigen
7.2.1.3. By Payload / Technology
7.2.1.4. By Linker Type
7.2.1.5. By Indication
7.2.1.6. By End User
7.2.1.7. By Country

8.1. Market Dynamics and Trends
8.1.1. Growth Drivers
8.1.2. Restraints
8.1.3. Opportunity
8.1.4. Key Trends

8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
8.2.1. Key Insights
8.2.1.1. By Product
8.2.1.2. By Target Antigen
8.2.1.3. By Payload / Technology
8.2.1.4. By Linker Type
8.2.1.5. By Indication
8.2.1.6. By End User
8.2.1.7. By Country

9.1. Market Dynamics and Trends
9.1.1. Growth Drivers
9.1.2. Restraints
9.1.3. Opportunity
9.1.4. Key Trends

9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
9.2.1. Key Insights
9.2.1.1. By Product
9.2.1.2. By Target Antigen
9.2.1.3. By Payload / Technology
9.2.1.4. By Linker Type
9.2.1.5. By Indication
9.2.1.6. By End User
9.2.1.7. By Country

10.1. Market Dynamics and Trends
10.1.1. Growth Drivers
10.1.2. Restraints
10.1.3. Opportunity
10.1.4. Key Trends

10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
10.2.1. Key Insights
10.2.1.1. By Product
10.2.1.2. By Target Antigen
10.2.1.3. By Payload / Technology
10.2.1.4. By Linker Type
10.2.1.5. By Indication
10.2.1.6. By End User
10.2.1.7. By Country

11.1. Zai Lab Ltd.
11.2. WuXi XDC
11.3. Takeda Pharmaceutical Co. Ltd
11.4. Synaffix BV
11.5. RemeGen Co., Ltd
11.6. Pfizer Inc. (Seagen Inc.)
11.7. Mersana Therapeutics Inc.
11.8. MacroGenics Inc.
11.9. Lonza Group AG
11.10. ImmunoGen Inc.
11.11. GSK plc
11.12. Gilead Sciences Inc.
11.13. Genmab A/S
11.14. F. Hoffmann-La Roche Ltd
11.15. Daiichi Sankyo Co. Ltd
11.16. Catalent Inc.
11.17. Bristol-Myers Squibb Co.
11.18. BioNTech SE
11.19. BeiGene Ltd.
11.20. AstraZeneca plc
11.21. Astellas Pharma Inc.
11.22. Amgen Inc.
11.23. ADC Therapeutics SA
11.24. AbbVie Inc.
11.25. Other Prominent Players

12.1. List of Secondary Sources
12.2. Key Country Markets- Macro Economic Outlook/Indicators